Durable Improvements in Clinical Outcomes with Alemtuzumab in Patients with Active Relapsing Remitting Multiple Sclerosis in the Absence of Continuous Treatment: 7-Year Follow-Up of CARE-MS I Patients (TOPAZ Study)

Jihad Said Inshasi, Alexey N Boyko, Jérôme De Seze, Hans-Peter Hartung, Eva Havrdova, Pamela McCombe, Xavier Montalban, Carlo Pozzilli, Patrick Vermersch, David H Margolin